JNJ Earnings: Broad Innovation & Top Line Performance

Johnson & Johnson (JNJ) looks undervalued with the market likely but not fully appreciating the broad innovation across the firm’s pipeline, notes Morningstar’s Damien Conover. He and Third Bridge’s Lee Brown discuss JNJ’s earnings. Brown suggests that JNJ’s top line performance was driven by the company innovative medicine segment.

Trading 360

17 Jul 2024

SHARE

Schwab Network's Newsletters

Daily insights for every investor

ON AIR
8:00 pm
Market Overtime
replay
12:00 am
The Wrap
REPLAY
12:30 am
Market On Close
REPLAY
2:00 am
Trading 360
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
7:30 pm
Market Overtime
REPLAY
ON AIR
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market On Close
REPLAY
10:00 pm
Trading 360
REPLAY
11:00 pm
The Wrap
REPLAY